EGFR and colorectal cancer: Multidisciplinary therapies, including systemic chemotherapy against unresectable and/or recurrent colorectal cancer, have improved, and FOLFOX, CapeOX and FOLFIRI combination chemotherapies plus bevacizumab or anti-EGFR monoclonal antibody can improve the survival times of patients.